The Effects of Jerusalem Artichoke and Fermented Soybean Powder Mixture Supplementation on Glucose Control

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02506582

Enrollment

Registered

2015-07-23

Start date

2013-06-30

Completion date

2015-01-31

Last updated

2015-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Newly Diagnosed Type 2 Diabetes, Prediabetes

Brief summary

The purpose of this randomized, double-blind, placebo-controlled study was to determine whether jerusalem artichoke and fermented soybeans powder mixture is effective in the control of blood glucose level in subjects with prediabetes or newly diagnosed type 2 diabetes.

Detailed description

The objective of this clinical study was to evaluate the effect of jerusalem artichoke and fermented soybean powder mixture supplementation on blood glucose. A randomized, double-blinded, placebo-controlled study was conducted on 60 subjects with impaired fasting glucose (IFG), impaired glucose tolerance (IGT) or newly diagnosed type 2 diabetes. The subjects were randomly assigned to either a group ingesting 40 g jerusalem artichoke and fermented soybean powder mixture supplementation daily or a placebo group for 12-week. We assessed fasting and postprandial levels of glucose.

Interventions

DIETARY_SUPPLEMENTjerusalem artichoke and fermented soybeans powder mixture

40 g jerusalem artichoke and fermented soybean powder mixture

DIETARY_SUPPLEMENTplacebo

40 g powdered rice flour

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

1\. All subjects were with prediabetes (IFG or IGT) or newly diagnosed type 2 DM (T2DM) no taking medicine. IFG was defined as fasting glucose between 100 and 125 mg/dL and IGT was defined as 2-h OGTTs glucose levels 140-199 mg/dL. Newly diagnosed type 2 diabetes was defined as fasting glucose ≥126 mg/dL or 2-h OGTTs level ≥ 200 mg/dL.

Exclusion criteria

1. glucose lowering medications or insulin injections; 2. abnormal liver or renal function; 3. chronic stomach and intestines disease; 4. chronic alcoholism; 5. pregnancy or intending to become pregnant during time of study. 6. complications; 7. an occupation that could be dangerous if hypoglycemia should occur.

Design outcomes

Primary

Measure	Time frame
Blood glucose level by 2-h oral glucose tolerance tests (OGTTs)	12 week

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026